Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sonidegib (LDE225) is an orally bioavailable small molecule inhibitor of the Smoothened (SMO) receptor, a key component of the Hedgehog (Hh) signaling pathway. Paclitaxel is a taxane-based chemotherapy agent that stabilizes microtubules, thereby interfering with cell division and inducing apoptosis. The combination of sonidegib and paclitaxel has been investigated in Phase I clinical trials, notably by the Swiss Group for Clinical Cancer Research (SAKK), for the treatment of advanced solid tumors and platinum-resistant ovarian cancer. The rationale for this combination is to target the Hedgehog pathway, which is often aberrantly activated in various cancers and contributes to tumor progression, maintenance of cancer stem cells, and resistance to conventional chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sonidegib + paclitaxel.